Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
Si-Bone, Inc. (SIBN) is a leader in minimally invasive surgical solutions for sacroiliac joint disorders, pioneering orthopedic innovations since its founding. This news hub provides investors and healthcare professionals with essential updates on the company's progress in medical device development and market expansion.
Comprehensive SIBN Coverage: Access official press releases and third-party analysis covering regulatory milestones, quarterly earnings, product launches (including iFuse System updates), clinical trial results, and strategic partnerships. Our curated feed eliminates speculation to deliver actionable information about this NASDAQ-listed innovator.
Strategic Insights: Track SIBN's advancements in sacroiliac joint fusion technology alongside broader industry trends in orthopedic devices. Discover how patented titanium implants and FDA-cleared systems position the company within competitive medical sectors.
Bookmark this page for real-time updates on SIBN's financial performance, surgical innovation developments, and leadership in addressing underdiagnosed pelvic health conditions through clinically validated solutions.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management will conduct a fireside chat on September 9, 2025, at 4:00 AM PT / 7:00 AM ET.
Investors can access the presentation through registration, and a live webcast will be available on SI-BONE's investor relations website. The webcast recording will remain accessible for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will conduct a fireside chat on August 12, 2025, at 3:00 PM ET.
Investors can access the presentation through a webcast by registering online, and the live audio will be available on the company's website investor section. The webcast recording will remain accessible for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET. Investors can access the call through registration and listen to the live webcast on SI-BONE's investor relations website. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami Beach. The company's management will conduct a fireside chat on June 10, 2025, at 8:20 AM PT/11:20 AM ET. Investors can access the live webcast through registration and the company's website. The webcast recording will be available for replay on SI-BONE's investor relations page for at least 90 days following the event.
SI-BONE Inc (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the 2025 BofA Securities Healthcare Conference in Las Vegas. The company's management will conduct a fireside chat on May 13, 2025, at 8:40 AM PT/11:40 AM ET. Investors can access the live webcast through a registration link or the company's website investor section. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, after market close. The company will hold a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can participate in the conference call by registering through the provided link. The webcast will be accessible through the company's website's 'Investors' section and will remain available for replay for at least 90 days following the event.
SI-BONE (SIBN) reported strong Q4 2024 financial results with worldwide revenue reaching $49.0 million, up 26% year-over-year. U.S. revenue grew 28% to $46.9 million. The company achieved positive adjusted EBITDA of $1.9 million in Q4, a 139% improvement.
For full-year 2024, worldwide revenue increased 20% to $167.2 million, with U.S. revenue up 21% to $158.4 million. The company reduced its net loss by 29% to $30.9 million. Gross margin remained stable at 79%.
Looking ahead, SI-BONE provided 2025 guidance, projecting worldwide revenue between $193.5-$195.5 million, representing 16-17% growth. The company expects to achieve positive adjusted EBITDA for both second half and full year 2025, with gross margins forecasted at 77-78%.
SI-BONE (SIBN) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors can participate in the conference call by registering through the provided link. The webcast will be available on the company's investor relations website and will remain accessible for replay for at least 90 days following the event.
FAQ
What is the current stock price of Si-Bone (SIBN)?
What is the market cap of Si-Bone (SIBN)?
